Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Apellis insiders caused the company to misrepresent or fail to disclose that (1) the design of SYFOVRE’s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, statements about the company’s business, operations, and prospects lacked a reasonable basis.

If you currently own Apellis and purchased prior to January 28, 2021 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814.  The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814